Patient affected by beta-propeller protein-associated neurodegeneration: A therapeutic attempt with iron vhelation therapy

Mattia Fonderico, Michele Laudisi, Nico Golfrè Andreasi, Stefania Bigoni, Costanza Lamperti, Celeste Panteghini, Barbara Garavaglia, Miryam Carecchio, Elia Antonio Emanuele, Gian L. Forni, Enrico Granieri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Here, we report the case of a 36-year-old patient with a diagnosis of de novo mutation of the WDR45 gene, responsible for beta-propeller protein-associated neurodegeneration, a phenotypically distinct, X-linked dominant form of Neurodegeneration with Brain Iron Accumulation. The clinical history is characterized by a relatively stable intellectual disability and a hypo-bradykinetic and hypertonic syndrome with juvenile onset. Genetic investigations and T1 and T2-weighted MR images align with what is described in literature. The patient was also subjected to PET with 18-FDG investigation and DaT-Scan study. In reporting relevant clinical data, we want to emphasize the fact that the patient received a chelation therapy with deferiprone (treatment already used in other forms of NBIA with encouraging results), which, however, had to be interrupted because the parkinsonian symptoms worsened. Conversely, the patient has benefited from nondrug therapies and, in particular, from an adapted motor activity with assisted pedaling (method in the process of validation in treatments of parkinsonian syndromes), which started before the treatment with deferiprone and still continues.

Original languageEnglish
Article number385
JournalFrontiers in Neurology
Volume8
Issue numberAUG
DOIs
Publication statusPublished - Aug 21 2017

Fingerprint

Iron
Proteins
Chelation Therapy
Parkinsonian Disorders
Therapeutics
Intellectual Disability
Foot
Motor Activity
Mutation
Genes
deferiprone

Keywords

  • Basal ganglia
  • Beta-propeller protein-associated neurodegeneration
  • Iron
  • Iron-chelating agents
  • NBIA disorders

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Patient affected by beta-propeller protein-associated neurodegeneration : A therapeutic attempt with iron vhelation therapy. / Fonderico, Mattia; Laudisi, Michele; Andreasi, Nico Golfrè; Bigoni, Stefania; Lamperti, Costanza; Panteghini, Celeste; Garavaglia, Barbara; Carecchio, Miryam; Emanuele, Elia Antonio; Forni, Gian L.; Granieri, Enrico.

In: Frontiers in Neurology, Vol. 8, No. AUG, 385, 21.08.2017.

Research output: Contribution to journalArticle

Fonderico, M, Laudisi, M, Andreasi, NG, Bigoni, S, Lamperti, C, Panteghini, C, Garavaglia, B, Carecchio, M, Emanuele, EA, Forni, GL & Granieri, E 2017, 'Patient affected by beta-propeller protein-associated neurodegeneration: A therapeutic attempt with iron vhelation therapy', Frontiers in Neurology, vol. 8, no. AUG, 385. https://doi.org/10.3389/fneur.2017.00385
Fonderico, Mattia ; Laudisi, Michele ; Andreasi, Nico Golfrè ; Bigoni, Stefania ; Lamperti, Costanza ; Panteghini, Celeste ; Garavaglia, Barbara ; Carecchio, Miryam ; Emanuele, Elia Antonio ; Forni, Gian L. ; Granieri, Enrico. / Patient affected by beta-propeller protein-associated neurodegeneration : A therapeutic attempt with iron vhelation therapy. In: Frontiers in Neurology. 2017 ; Vol. 8, No. AUG.
@article{400e4e5af6e94ef1b04959647083cbbb,
title = "Patient affected by beta-propeller protein-associated neurodegeneration: A therapeutic attempt with iron vhelation therapy",
abstract = "Here, we report the case of a 36-year-old patient with a diagnosis of de novo mutation of the WDR45 gene, responsible for beta-propeller protein-associated neurodegeneration, a phenotypically distinct, X-linked dominant form of Neurodegeneration with Brain Iron Accumulation. The clinical history is characterized by a relatively stable intellectual disability and a hypo-bradykinetic and hypertonic syndrome with juvenile onset. Genetic investigations and T1 and T2-weighted MR images align with what is described in literature. The patient was also subjected to PET with 18-FDG investigation and DaT-Scan study. In reporting relevant clinical data, we want to emphasize the fact that the patient received a chelation therapy with deferiprone (treatment already used in other forms of NBIA with encouraging results), which, however, had to be interrupted because the parkinsonian symptoms worsened. Conversely, the patient has benefited from nondrug therapies and, in particular, from an adapted motor activity with assisted pedaling (method in the process of validation in treatments of parkinsonian syndromes), which started before the treatment with deferiprone and still continues.",
keywords = "Basal ganglia, Beta-propeller protein-associated neurodegeneration, Iron, Iron-chelating agents, NBIA disorders",
author = "Mattia Fonderico and Michele Laudisi and Andreasi, {Nico Golfr{\`e}} and Stefania Bigoni and Costanza Lamperti and Celeste Panteghini and Barbara Garavaglia and Miryam Carecchio and Emanuele, {Elia Antonio} and Forni, {Gian L.} and Enrico Granieri",
year = "2017",
month = "8",
day = "21",
doi = "10.3389/fneur.2017.00385",
language = "English",
volume = "8",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "AUG",

}

TY - JOUR

T1 - Patient affected by beta-propeller protein-associated neurodegeneration

T2 - A therapeutic attempt with iron vhelation therapy

AU - Fonderico, Mattia

AU - Laudisi, Michele

AU - Andreasi, Nico Golfrè

AU - Bigoni, Stefania

AU - Lamperti, Costanza

AU - Panteghini, Celeste

AU - Garavaglia, Barbara

AU - Carecchio, Miryam

AU - Emanuele, Elia Antonio

AU - Forni, Gian L.

AU - Granieri, Enrico

PY - 2017/8/21

Y1 - 2017/8/21

N2 - Here, we report the case of a 36-year-old patient with a diagnosis of de novo mutation of the WDR45 gene, responsible for beta-propeller protein-associated neurodegeneration, a phenotypically distinct, X-linked dominant form of Neurodegeneration with Brain Iron Accumulation. The clinical history is characterized by a relatively stable intellectual disability and a hypo-bradykinetic and hypertonic syndrome with juvenile onset. Genetic investigations and T1 and T2-weighted MR images align with what is described in literature. The patient was also subjected to PET with 18-FDG investigation and DaT-Scan study. In reporting relevant clinical data, we want to emphasize the fact that the patient received a chelation therapy with deferiprone (treatment already used in other forms of NBIA with encouraging results), which, however, had to be interrupted because the parkinsonian symptoms worsened. Conversely, the patient has benefited from nondrug therapies and, in particular, from an adapted motor activity with assisted pedaling (method in the process of validation in treatments of parkinsonian syndromes), which started before the treatment with deferiprone and still continues.

AB - Here, we report the case of a 36-year-old patient with a diagnosis of de novo mutation of the WDR45 gene, responsible for beta-propeller protein-associated neurodegeneration, a phenotypically distinct, X-linked dominant form of Neurodegeneration with Brain Iron Accumulation. The clinical history is characterized by a relatively stable intellectual disability and a hypo-bradykinetic and hypertonic syndrome with juvenile onset. Genetic investigations and T1 and T2-weighted MR images align with what is described in literature. The patient was also subjected to PET with 18-FDG investigation and DaT-Scan study. In reporting relevant clinical data, we want to emphasize the fact that the patient received a chelation therapy with deferiprone (treatment already used in other forms of NBIA with encouraging results), which, however, had to be interrupted because the parkinsonian symptoms worsened. Conversely, the patient has benefited from nondrug therapies and, in particular, from an adapted motor activity with assisted pedaling (method in the process of validation in treatments of parkinsonian syndromes), which started before the treatment with deferiprone and still continues.

KW - Basal ganglia

KW - Beta-propeller protein-associated neurodegeneration

KW - Iron

KW - Iron-chelating agents

KW - NBIA disorders

UR - http://www.scopus.com/inward/record.url?scp=85028429619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028429619&partnerID=8YFLogxK

U2 - 10.3389/fneur.2017.00385

DO - 10.3389/fneur.2017.00385

M3 - Article

AN - SCOPUS:85028429619

VL - 8

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - AUG

M1 - 385

ER -